secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001437749-25-034618
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar Therapeutics Q3 2025 net loss $3.4M; cash $143.7M; NDA for ALXN1840 planned early 2026
--------------------------------------------------------------------------------

- Net loss $3.4M ($0.48/sh) vs $1.3M ($0.37/sh) in Q3 2024; no revenue reported.
- Cash, equivalents & investments $143.7M as of Sep 30, 2025; funds expected through Dec 2027.
- NDA submission to FDA for ALXN1840 in Wilson disease targeted for early 2026.
- Raised ~$126.9M gross in public offering; $35M used to repurchase 550,229 shares from Tactic Pharma, net ~$91.9M.
- FDA cleared IND for MNPR-101-Lu therapeutic radiopharmaceutical trial in solid tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774925034618/0001437749-25-034618-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774925034618/mnpr20251105_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-034618

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer